Adverse clinical complications after surviving a myocardial infarction (MI) now represent a major health issue in Australia. Up to 20% of MI survivors suffer subsequent heart failure, which leads to impaired cardiac function and high levels of morbidity and mortality despite patients receiving contemporary treatments and best practice clinical care. This project is innovative in that it will test whether synthetic drugs, that selectively inhibit the neutrophil enzyme myeloperoxidase (MPO), can inhibit cardiac inflammation following MI and whether decreasing inflammation in the heart prevents and/or reverses secondary cardiac damage and adverse remodeling, which together decrease the risk of heart failure in survivors of MI.
Last updated12 March 2024